Trial Profile
A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Mepacrine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 28 Oct 2016 Status changed from recruiting to completed.
- 16 Mar 2016 Phase of the study changed from phase I/II to phase I, accordingly treatment table, study title, purpose of the study had been modified, according to ClinicalTrials.gov record.
- 16 Mar 2016 Planned number of patients changed from 70 to 24, according to ClinicalTrials.gov record.